81 studies found for:    vaccine adverse reactions | Open Studies
Show Display Options
Download search resultsDownload the search results for:
vaccine adverse reactions | Open Studies (81 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Not yet recruiting VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Condition: Smallpox Vaccine Adverse Reaction
Intervention: Biological: Vaccination with ACAM2000
2 Recruiting Hepatitis B Vaccination in Infants
Conditions: Meningococcal Disease;   Pneumococcal Disease;   Haemophilus Influenzae Serotype b Disease;   Diphtheria, Tetanus and Pertussis;   Hepatitis b
Interventions: Biological: Menjugate;   Biological: Menitorix;   Biological: NeisVac-C
3 Recruiting A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Condition: Ebola Virus Disease
Interventions: Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo
4 Not yet recruiting Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Condition: Condylomata Acuminata
Interventions: Biological: low dosage HPV Vaccine;   Biological: medium dosage HPV Vaccine;   Biological: high dosage HPV Vaccine;   Biological: Aluminium Adjuvant
5 Not yet recruiting Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older
Condition: Pneumococcal 13-valent Conjugate Vaccine
Interventions: Biological: One dose of PCV13a vaccine;   Biological: three doses of PCV13a vaccine
6 Not yet recruiting The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans
Conditions: Rabies;   Healthy
Interventions: Biological: 2.5IU/ml in rabies vaccine (MRC-5 Cell) humans aged 10-20 years old;   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans aged 21-60 years old;   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans(from 10-20 years old);   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans(from 21-60 years old)
7 Recruiting A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
Condition: Hepatitis E
Intervention: Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
8 Not yet recruiting Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older
Condition: Herpes Zoster
Interventions: Biological: the vaccine with high doses of virus content between 4.7~5.0 lgPFU;   Biological: the vaccine with low doses of virus content between 4.7~5.0 lgPFU;   Biological: the vaccine with high doses of virus content between 4.3~5.0 lgPFU;   Biological: the vaccine with middle doses of virus content between 4.3~5.0 lgPFU;   Biological: the vaccine with low doses of virus content between 4.3~5.0 lgPFU;   Biological: placebo
9 Not yet recruiting Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
Condition: Dengue
Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine;   Other: Placebo
10 Not yet recruiting A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Condition: Pneumonia
Interventions: Biological: 13-valent pneumococcal conjugate vaccine;   Biological: 7-valent pneumococcal conjugate vaccine
11 Recruiting Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children
Condition: Immune Response to MMR Vaccine
Intervention: Biological: MMR vaccine
12 Unknown  Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
Condition: Influenza
Intervention: Biological: 2012 trivalent influenza vaccine
13 Recruiting VZV Vaccine for Hematopoietic Stem Cell Transplantation
Condition: Varicella Zoster Infection
Interventions: Biological: Zostavax;   Biological: Normal Saline
14 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
15 Recruiting A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population Aged 5 Through to 17 Years of Age
Condition: Influenza, Human
Interventions: Biological: bioCSL QIV;   Biological: Comparator QIV
16 Not yet recruiting Vivotif Release Titers (USA)
Condition: Typhoid Fever
Intervention: Biological: Vivotif
17 Recruiting The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination
Condition: Varicella
Interventions: Biological: HBV-3;   Biological: HBV-6;   Biological: varicella-3;   Biological: varicella-6
18 Recruiting Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma
Interventions: Biological: Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001;   Other: Laboratory Biomarker Analysis
19 Unknown  Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Conditions: Immunogenicity;   Reactogenicity
Intervention: Biological: Trivivac vaccine
20 Unknown  Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
Conditions: HIV-1 Infection;   Cancer;   Immunosuppression
Intervention: Other: serologic testing

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years